Unexpected outcome (positive or negative) including adverse drug reactions
New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis
1 Medical University Hospital Graz, Division of Rheumatology, Auenbruggerplatz 15, Graz, 8036, Austria
2 University Hospital Graz, Department for Dermatology and Venerology, Auenbruggerplatz 8, Graz, 8036, Austria
Correspondence to:
Christina Jost, christina.jost{at}klinikum-graz.at
Administration of abatacept is a new treatment modality for rheumatoid arthritis (RA). We describe a patient in whom psoriasiform skin lesions developed 4 months after the initiation of abatacept therapy for longstanding, rheumatoid factor positive RA. Histological findings were consistent with psoriasis. The skin lesions subsided after discontinuation of abatacept and reappeared after re-exposure to the drug, suggesting a causal connection between abatacept and the development of psoriasis.
Register for free content
The full text of all Editor's Choice articles and summaries of every article are free without registration
The full text of Images in ... articles are free to registered users
Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource
Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog
